Consensus in stem cell transplantation for pediatric lymphomas
Open Access
- 22 January 2025
- journal article
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Abstract
Lymphomas are the third most common childhood cancer in Brazil. Management is predicated on precise diagnosis and staging through clinical, pathological, molecular, and radiological evaluation. Although the prognosis for pediatric non-Hodgkin and Hodgkin lymphoma has improved markedly, relapsed or refractory cases remain a clinical challenge. For these patients, aggressive chemotherapy followed by autologous or allogeneic hematopoietic cell transplantation serves as a vital salvage strategy. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This revision also includes the assessment of new therapeutic strategies, including immunotherapy and CAR-T cell therapy, for eligible patients.Keywords
This publication has 61 references indexed in Scilit:
- CHIMERIC ANTIGEN RECEPTOR T‐CELLS (CAR‐T) FOR REFRACTORY AND RELAPSED BURKITT'S LYMPHOMA: EARLY RESPONSE IN PEDIATRIC PATIENTSHematological Oncology, 2019
- Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaTransplantation and Cellular Therapy, 2018
- T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related DonorsTransplantation and Cellular Therapy, 2018
- Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapyAnnals of Hematology, 2015
- Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2015
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on OutcomeTransplantation and Cellular Therapy, 2013
- Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid MalignanciesTransplantation and Cellular Therapy, 2011
- Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and AdolescentsTransplantation and Cellular Therapy, 2010
- Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell TransplantationTransplantation and Cellular Therapy, 2006
- Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphomaAnnals of Hematology, 2002